Erasca Under Investigation for Securities Law Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: Globenewswire
- Stock Price Plunge: Erasca, Inc. shares fell over 45% in premarket trading on April 28, 2026, after receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, leading to a significant loss of investor confidence.
- Legal Investigation Initiated: Block & Leviton is investigating whether Erasca violated securities laws and may file a lawsuit to recover losses on behalf of investors, a move that could further impact the company's reputation and shareholder trust.
- Investor Remediation Options: All investors who have lost money in Erasca are encouraged to contact Block & Leviton to learn how to pursue legal recovery, potentially prompting more investors to take action and affecting the company's future shareholder structure.
- Whistleblower Reward Program: Block & Leviton is urging whistleblowers with non-public information to assist in the investigation, with rewards of up to 30% of any successful recovery, a policy that may attract more insiders to participate and increase the legal risks faced by the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 12.200
Low
2.00
Averages
5.50
High
11.00
Current: 12.200
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RTW Investments Increases Stake in Erasca
- Stake Increase: RTW Investments disclosed in a May 15, 2026 SEC filing that it acquired 16,010,524 shares of Erasca, valued at approximately $189.23 million, indicating strong confidence in the company's prospects.
- Value Growth: As of March 31, 2026, RTW's total stake in Erasca reached $261.42 million, an increase of $260.88 million from the previous quarter, reflecting optimistic market expectations for Erasca's future developments.
- Outstanding Market Performance: Erasca's shares are priced at $12.84, having surged nearly 800% over the past year, significantly outperforming the S&P 500's 28% increase, showcasing growing investor confidence in its research pipeline.
- Strong Financial Position: As of March 2026, Erasca had $408.5 million in cash and marketable securities, expected to fund operations into the second half of 2028, enhancing its research capabilities and competitive position in cancer treatment.
See More
RTW Investments Increases Stake in Erasca
- Increased Holdings: RTW Investments acquired 16,010,524 shares of Erasca in Q1 2026, with an estimated transaction value of $189.23 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The quarter-end value of Erasca's holdings reached $261.42 million, reflecting an increase of $260.88 million from the previous quarter, driven by both share price appreciation and additional purchases.
- R&D Progress: Erasca's lead program, ERAS-0015, has shown promising early responses in patients with KRAS-driven lung and pancreatic cancers, with the CEO highlighting its potential as a future
See More
Erasca Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of Erasca, Inc. investors whether the company has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, which could lead to legal liabilities.
- Stock Price Plunge: Following the news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, indicates that if the allegations are substantiated, Erasca may face substantial damages and reputational harm, impacting its future financing capabilities.
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws and other unlawful business practices, indicating serious concerns regarding the company's compliance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 drug infringes on a patent and involves trade secret misappropriation, which could lead to increased legal liabilities.
- Stock Price Plummet Impact: Following the allegations, Erasca's stock price fell from $19.15 on April 27 to $9.90, a 48% drop, reflecting market pessimism about the company's future prospects.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to contact attorneys to discuss their legal rights, demonstrating the firm's commitment to protecting investor interests and its expertise in securities litigation.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its share price plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge regarding intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, severely impacting investor confidence.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's lead product candidate ERAS-0015, claiming patent infringement and demanding an immediate halt to its sales, which could inflict long-term damage on Erasca's market position.
- Investor Investigation Launched: In response to the severe market reaction, Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its ERAS-0015 intellectual property, potentially leading to further legal liabilities and financial losses.
- Uncertain Product Development Outlook: Erasca previously claimed that ERAS-0015 had a competitive edge over RevMed's RMC-6236, but the emergence of this legal challenge has cast doubt on the product's market prospects, potentially affecting future financing and research and development plans.
See More
Paradigm Sells Over 3.7 Million Shares of Erasca
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
See More
RTW Investments Increases Stake in Erasca
- Stake Increase: RTW Investments disclosed in a May 15, 2026 SEC filing that it acquired 16,010,524 shares of Erasca, valued at approximately $189.23 million, indicating strong confidence in the company's prospects.
- Value Growth: As of March 31, 2026, RTW's total stake in Erasca reached $261.42 million, an increase of $260.88 million from the previous quarter, reflecting optimistic market expectations for Erasca's future developments.
- Outstanding Market Performance: Erasca's shares are priced at $12.84, having surged nearly 800% over the past year, significantly outperforming the S&P 500's 28% increase, showcasing growing investor confidence in its research pipeline.
- Strong Financial Position: As of March 2026, Erasca had $408.5 million in cash and marketable securities, expected to fund operations into the second half of 2028, enhancing its research capabilities and competitive position in cancer treatment.
See More
RTW Investments Increases Stake in Erasca
- Increased Holdings: RTW Investments acquired 16,010,524 shares of Erasca in Q1 2026, with an estimated transaction value of $189.23 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The quarter-end value of Erasca's holdings reached $261.42 million, reflecting an increase of $260.88 million from the previous quarter, driven by both share price appreciation and additional purchases.
- R&D Progress: Erasca's lead program, ERAS-0015, has shown promising early responses in patients with KRAS-driven lung and pancreatic cancers, with the CEO highlighting its potential as a future
See More
Erasca Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of Erasca, Inc. investors whether the company has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, which could lead to legal liabilities.
- Stock Price Plunge: Following the news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, reflecting extreme pessimism in the market regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, indicates that if the allegations are substantiated, Erasca may face substantial damages and reputational harm, impacting its future financing capabilities.
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws and other unlawful business practices, indicating serious concerns regarding the company's compliance.
- Patent Infringement Allegations: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 drug infringes on a patent and involves trade secret misappropriation, which could lead to increased legal liabilities.
- Stock Price Plummet Impact: Following the allegations, Erasca's stock price fell from $19.15 on April 27 to $9.90, a 48% drop, reflecting market pessimism about the company's future prospects.
- Investor Rights Protection: Bragar Eagel & Squire encourages affected investors to contact attorneys to discuss their legal rights, demonstrating the firm's commitment to protecting investor interests and its expertise in securities litigation.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its share price plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge regarding intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, severely impacting investor confidence.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's lead product candidate ERAS-0015, claiming patent infringement and demanding an immediate halt to its sales, which could inflict long-term damage on Erasca's market position.
- Investor Investigation Launched: In response to the severe market reaction, Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its ERAS-0015 intellectual property, potentially leading to further legal liabilities and financial losses.
- Uncertain Product Development Outlook: Erasca previously claimed that ERAS-0015 had a competitive edge over RevMed's RMC-6236, but the emergence of this legal challenge has cast doubt on the product's market prospects, potentially affecting future financing and research and development plans.
See More
Paradigm Sells Over 3.7 Million Shares of Erasca
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
See More
